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Retina
Susceptibility of Streptozotocin-Induced Diabetic Rat
Retinal Function and Ocular Blood Flow to Acute
Intraocular Pressure Challenge
Vickie H. Y. Wong,1 Algis J. Vingrys,1 Andrew I. Jobling,2 and Bang V. Bui1
PURPOSE. To consider the hypothesis that streptozotocin (STZ)-
induced hyperglycemia renders rat retinal function and ocular
blood flow more susceptible to acute IOP challenge.
METHODS. Retinal function (electroretinogram [ERG]) was
measured during acute IOP challenge (10–100 mm Hg,
increments of 5 mm Hg, 3 minutes per step, vitreal
cannulation) in adult Long-Evans rats (6 weeks old; citrate: n
¼6, STZ: n¼10) 4 weeks after citrate buffer or STZ (65 mg/kg,
blood glucose >15 mM) injection. At each IOP, dim and bright
flash (4.56,1.72 log cd.s.m2) ERG responses were recorded
to measure inner retinal and ON-bipolar cell function,
respectively. Ocular blood flow (laser Doppler flowmetry;
citrate: n¼6, STZ: n¼10) was also measured during acute IOP
challenge. Retinas were isolated for quantitative PCR analysis of
nitric oxide synthase mRNA expression (endothelial, eNos;
inducible, iNos; neuronal, nNos).
RESULTS. STZ-induced diabetes increased the susceptibility of
inner retinal (IOP at 50% response, 60.1, CI: 57.0–62.0 mm Hg
versus citrate: 67.5, CI: 62.1–72.4 mm Hg) and ON-bipolar cell
function (STZ: 60.3, CI: 58.0–62.8 mm Hg versus citrate: 65.1,
CI: 61.9–68.6 mm Hg) and ocular blood flow (43.9, CI: 40.8–
46.8 versus citrate: 53.4, CI: 50.7–56.1 mm Hg) to IOP
challenge. Citrate eyes showed elevated eNos mRNA (þ49.7%)
after IOP stress, an effect not found in STZ-diabetic eyes
(5.7%, P < 0.03). No difference was observed for iNos or
nNos (P > 0.05) following IOP elevation.
CONCLUSIONS. STZ-induced diabetes increased functional sus-
ceptibility during acute IOP challenge. This functional
vulnerability is associated with a reduced capacity for diabetic
eyes to upregulate eNos expression and to autoregulate blood
flow in response to stress. (Invest Ophthalmol Vis Sci. 2013;
54:2133–2141) DOI:10.1167/iovs.13-11595
A major complication affecting many patients with diabetesis retinopathy, which is clinically characterized by vascular
abnormalities, such as microaneurysms, hemorrhages, and
neovascularization, which can lead to vision loss.1 There is
growing evidence that neuronal abnormalities might precede
microangiopathy.2 For example, functional assessment of the
retina using electrophysiological measures reveals changes in
function3,4 prior to clinically detectable microangiopathy.
Indeed, Bearse et al.5 and Harrison et al.6 provide evidence
that regions of the retina showing functional deficits are more
likely to go on to show signs of microangiopathy. The presence
of neuronal dysfunction may reflect subtle changes to the
vasculature not readily detectable clinically. Evidence in
clinical studies (none or mild nonproliferative diabetic
retinopathy)7–9 and in animal models suggest that changes in
retinal blood flow,10 impaired blood vessel reactivity,11–13 and
autoregulation14 occur early in the course of the disease.
In addition to the development of diabetic retinopathy, the
presence of vascular dysfunction or some inherent neuronal
weakness may place diabetic eyes at greater risk of other
neurodegenerative diseases, such as glaucoma. Glaucoma
affects an estimated 60 million people worldwide15 and is
characterized by a progressive loss of retinal ganglion cells. The
most well-defined risk factor for glaucoma is elevated
intraocular pressure (IOP). Epidemiological studies have
returned conflicting outcomes as to whether diabetes increas-
es the risk of glaucoma (as reviewed in Wong et al.16).
However, these studies did not set out to directly consider the
association between diabetes and glaucoma. Laboratory studies
provide some evidence in support of this possibility. Kanamori
et al.17 reported that streptozotocin (STZ)-induced hypergly-
cemic rats showed greater apoptosis of retinal neurons after
exposure to chronic IOP elevation compared with normogly-
cemic rats. Kohzaki et al.18 showed a reduction in the recovery
of retinal ganglion cell responses 1 week after a single episode
of IOP challenge, an effect not evident in citrate control rats.
Whether this increased susceptibility arises from impairment
to the vascular system or via a deficit in retinal neurons is not
clear.
This study considered the hypothesis that STZ-induced
hyperglycemia increases susceptibility of the electroretino-
gram and ocular blood flow to acute IOP challenge. In the
same cohort of animals, we also consider a potential
mechanism by comparing the effect of IOP challenge on gene
expression of nitric oxide synthase (Nos)-isoenzymes (endo-
thelial, eNos; inducible, iNos; neuronal, nNos) in diabetic and
control eyes.
METHODS
Animals
All experimental procedures abide with the ARVO Statement for the
Use of Animals in Ophthalmic and Vision Research and the National
Health and Medical Research Council’s Australian Code of Practice for
the care and use of animals for scientific purposes. Animal ethics
approval was obtained from the Faculty of Science Animal Ethics
Committee at The University of Melbourne. Hyperglycemia was
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induced in 6-week-old male Long-Evans rats (Monash Animal Services,
Clayton, Victoria, Australia) via a tail vein injection of 65 kg/mg STZ
(MP Biomedicals, Seven Hills, New South Wales, Australia) dissolved in
0.1 M sodium citrate buffer (pH 4.5; Sigma-Aldrich Pty Ltd., Castle Hill,
New South Wales, Australia). Animals were fasted overnight (~12
hours) prior to STZ-injection. Control animals were given tail vein
injections of 0.1 M sodium citrate buffer (citrate group). One week
following STZ-injection, blood glucose (Table 1) was measured
(Ascensia Esprit Glucometer; Bayer Australia, Ltd., Pymble, New South
Wales, Australia) to confirm that all STZ-treated animals had blood
glucose higher than 15 mM. To prevent ketoacidosis and excessive loss
of body weight, 2 units of insulin was administered each day for 2
weeks. After 2 weeks, only those animals with blood glucose higher
than 20 mM continued to receive insulin injection (2 units/d). Animals
were housed in a 228C environment with a 12:12-hour light-dark cycle
(maximum 40 lux), with normal rat chow (Barastoc rat chow; Ridley
AgriProducts, Melbourne, Victoria, Australia) and water available ad
libitum.
Electrophysiology and blood flow measurement were conducted
under general anesthesia (ketamine-xylazine, 60:5 mg/kg, intramuscu-
larly [IM]). It is worth noting that ketamine-xylazine anesthesia may
have neuroprotective effects19; however, our low dose of ketamine
should provide similar effects in both citrate control and STZ-injected
animals. A topical anesthetic (0.5% proxymetacaine hydrochloride, eye
drops, Alcaine, 5 mg/mL; Alcon Laboratories, Frenchs Forest, New
South Wales, Australia) and a mydriatic (0.5% tropicamide, Mydriacyl, 5
mg/mL; Alcon Laboratories) were also given. A circulating water heat
pad was used to maintain body temperature at approximately 378C.
Acute IOP Elevation
Baseline IOP was obtained from each animal using a noninvasive
applanation tonometer (Tonopen XL; Medtronic Solan, Jacksonville,
FL) using light sedation (50% dose, ketamine-xylazine, 30 mg/kg:2.5
mg/kg, IM). This established that STZ treatment did not affect baseline
IOP (Table 1). To ensure that any functional and ocular blood flow
susceptibility is independent of ocular perfusion pressure (blood
pressure IOP), systolic blood pressure (SBP, Table 1) was assayed via
noninvasive tail cuff sphygmomanometer (ML125; ADInstruments Pty,
Ltd., Bella Vista, New South Wales, Australia). To assess ocular
susceptibility to stress, one randomly selected eye underwent
manometric IOP elevation from 10 to 100 mm Hg in increments of 5
mm Hg (3 minutes per step) using a height-adjustable reservoir (Hanks
balanced salt solution; Sigma-Aldrich Pty Ltd.) attached to a 30-gauge
cannula via polyethylene tubing. For electroretinogram (ERG) assess-
ment, the cannula was inserted into the vitreal chamber to allow for
placement of ERG electrodes. In those animals undergoing blood-flow
studies, a laser Doppler flowmetry (LDF) (ML191; ADInstruments Pty,
Ltd.) needle probe (MNP110XP; ADInstruments Pty, Ltd.) was inserted
into the vitreal chamber and, thus, IOP was manometrically controlled
via an anterior chamber cannula. Previously, we have shown that the
pressure between the anterior and vitreal chamber quickly equilibrates
regardless of the location of the cannula.20
Electroretinography
Prior to functional measurements, all animals were dark-adapted
overnight (approximately 12 hours) and procedures were conducted
in the dark with the aid of night-vision goggles (NVMT24021; Yukon
Advanced Optics, Sellmark Corporation, Mansfield, TX) and an infrared
light (IR) source (k¼ 880 nm, 18-LED IR spotlight; Jaycar, Rydalmere,
New South Wales, Australia) adapted onto a dissecting microscope
(Zeiss OPMI-1 Lab; Carl Zeiss Pty, Ltd., Jena, Germany).
Baseline ERG was measured 3 weeks following STZ or citrate
treatment. Responses were measured across a range of calibrated
(IL1700; International Light Technologies, Inc., Newbury Port, MA)
luminous energies (6.79 to 2.07 log cd.s.m2) delivered via a Ganzfeld
integrating sphere (170 mm diameter; Photometric Solutions Interna-
tional, Huntingdale, Victoria, Australia). This range returns measures of
photoreceptoral (a-wave)21 and ON-bipolar cell (b-wave).22 The
dimmest flashes elicit the scotopic threshold response (STR), which
provides information about the integrity of retinal ganglion cells.23–25
To quantify functional susceptibility to acute IOP challenge, ERGs
were recorded 4 weeks following citrate or STZ injection (1 week after
baseline assessment). Two luminous energies were assayed at each step
of IOP elevation. The first luminous energy was chosen to elicit an ERG
dominated by a rod-driven b-wave (1.42 log cd.s.m2), which has
been widely used to assay the effects of ischemia and IOP stress.20,26,27
The second, much dimmer, luminous energy (5.25 log cd.s.m2) was
chosen to elicit a retinal ganglion cell–dominated STR, a component of
the ERG known to be particularly sensitive to IOP elevation.
ERGs were recorded using custom-made corneal (active) and scleral
(reference, ring-shaped) chlorided silver electrodes (99.99% purity,
0.329 mm, 29-gauge; A&E Metal Merchants, Sydney, New South Wales,
Australia). Both electrodes from each eye were grounded to a stainless
steel electrode (F-E2-30; Grass Telefactor, West Warwick, RI) inserted
subcutaneously into the tail. Eyes were lubricated after electrode
placement and periodically throughout the session with 1.0%
carboxymethylcellulose sodium (Celluvisc; Allergan, Irvine, CA).
Signals were digitized at 4 kHz (ML785, Powerlab/8SP, 10003
amplification; ADInstruments Pty, Ltd.), with band pass settings of 3
dB at 0.3 to 1000 Hz.
Ocular Blood Flow: Laser Doppler Flowmetry
Ocular blood flow was measured using LDF (ML191; ADInstruments
Pty, Ltd.) as has been used previously.28–30 This approach provides real-
time continuous measurement of tissue microvascular perfusion. In the
eye, LDF reflects both retinal and choroidal blood flow,27 thus the term
‘‘ocular blood flow’’ (OBF) is used throughout the study.
The LDF needle probe (0.48 mm outer diameter3 25 mm length;
MNP110XP; ADInstruments Pty, Ltd.) was inserted 2 mm behind the
limbus, into the vitreal chamber. Both the LDF probe and IOP cannula
(anterior chamber) were stabilized and positioned with micromanip-
ulators (MM-3; Narishige Co., Ltd., Tokyo, Japan).
Retinal Tissue Isolation and Real-Time PCR
On completion of in vivo experiments, eyes were enucleated and
animals were euthanized (0.3 mL pentobarbitone sodium, Lethabarb;
Virbac Pty, Ltd., Peakhurst, New South Wales, Australia). Retinas were
excised, snap frozen in liquid nitrogen, and stored at 808C for RNA
isolation. Real-time quantitative PCR was conducted, for control and
IOP-treated eyes in both citrate and STZ-treated groups, to quantify
mRNA expression for specific target genes of interest (nNos, eNos, and
iNos) relative to a housekeeping gene (hypoxanthine phosphorylribo-
TABLE 1. Metabolic Parameters (Blood Glucose, IOP, and Systolic Blood Pressure; Mean 6 SEM) of Control and Diabetic Animals
Week
Blood Glucose, mM 6 SEM IOP, mm Hg 6 SEM
BP
SBP, mm Hg 6 SEM
Citrate STZ-Diabetes Citrate STZ-Diabetes Citrate STZ-Diabetes
1 5.8 6 0.2 23.1 6 0.9* 13.4 6 0.4 13.4 6 0.5 1 110.2 6 7.6 110.3 6 4.2
2 5.3 6 0.2 21.6 6 1.0* 2 92.0 6 5.5 102.7 6 3.9
* Denotes significance (P < 0.001) between citrate and STZ-diabetic animals for blood glucose (mM).
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syl transferase [HPRT]). For oligonucleotide primer sequences, see
Table 2.
RNA was isolated from dissected retinal tissue using a commercially
available kit (RNeasy Mini Kit; Qiagen Pty, Ltd., Doncaster, Victoria,
Australia). Isolated retinas were homogenized and treated with DNase-I
to eliminate possible contamination by genomic DNA. The purified
RNA (103 dilution with RNase-free dH2O) was then quantified using a
spectrophotometer (UV-2550; Shimadzu Corporation, Tokyo, Japan).
RNA concentration was determined by the absorbance at 260 nm
(RNeasy Mini Handbook for RNeasy Mini Kit, 2006; Qiagen Pty, Ltd.).
A 500-ng volume of purified RNA was transcribed to cDNA via
reverse transcription (RT) reaction. An Omniscript RT Kit (Qiagen Pty,
Ltd.) was used in combination with 0.5 lM oligo d(T) primers to
synthesize cDNA. These samples were incubated at 378C for 1 hour,
followed by dilution in dH2O into 5 ng/lL aliquots and stored at208C.
This was followed by RT (M-MLV Reverse Transcriptase, 200 l/lL and
Random Hexamers, 20 lg; Promega Corporation, Alexandria, New
South Wales, Australia).
The resultant cDNA was amplified by using real-time PCR (Light-
Cycler 3 Carousel-based system; Roche Diagnostics Australia Pty, Ltd.,
Castle Hill, New South Wales, Australia). The cDNA sample (1 lL) in
dH2O was combined with a master mix containing magnesium
chloride (MgCl2), reverse and forward primers (Sigma-Aldrich Pty,
Ltd.) and a reaction medium (FastStart DNA Master SYBR Green I;
Roche Diagnostics Australia Pty, Ltd.). To quantify the amount of gene
transcript, an external standard (the respective PCR-amplified cDNA
products) was serially diluted to produce a four-point standard curve. A
gene copy number was calculated for each dilution for post hoc
analysis. All real-time PCR samples were amplified in sets of triplicates
to minimize handling error. PCR results were analyzed using Light-
Cycler Data Analysis software (v 3.5.28; Roche Molecular Diagnostics,
Pleasanton, CA).
Data Analysis
Photoreceptoral Response. The leading edge of the scotopic a-
wave (PIII) was modeled (Equation 1),31 returning a measure of
photoreceptoral function. The summed rod photoreceptor response
(PIII) as a function of time (t, seconds) and luminous energy (i, log
cd.s.m2), given by a maximal amplitude (RmPIII, lV), a sensitivity (S,
log [m2.cd1.s3]), and a brief delay (td, seconds; largely recording
equipment delay),
PIIIði; tÞ ¼ RmPIII  1 exp

 i  S  ðt  tdÞ2
h i
; t > td : ð1Þ
This function was modeled over an ensemble of the 2 brightest
luminous energies (1.95 and 2.07 log cd.s.m2). The delay (td) was 4.07
6 0.05 and 4.15 6 0.03 ms for citrate and STZ-treated groups,
respectively. These td values were then fixed; thus, only S and RmPIII
were allowed to float in the final model, which was optimized by
minimizing the sum-of-squares merit function using the Excel Solver
module (Microsoft, Redmond, WA).
Rod and Cone ON-Bipolar Cell Responses. To isolate the ON-
bipolar cell component of the ERG (PII), the modeled PIII was
subtracted from the raw waveform.32 PII amplitudes measured at a
fixed time of 70 ms were plotted as a function of luminous energy
and modeled using a saturating hyperbolic function, as given in
Equation 2. The amplitude (V, lV) as a function of luminous energy (i,
log cd.s.m2) is given by a maximal amplitude (Vmax, lV), semi-
saturation constant (k, log cd.s.m2), where sensitivity is 1/k
(cd1.s1.m2) and n is a dimensionless exponent that determines the
slope of the function.
V ðiÞ ¼ Vmax i
n
in þ kn ð2Þ
The dark-adapted ERG reflects contributions from both rod and cone
pathways. Therefore, Equation 2 was fit to luminous energies below
those containing cone responses. This was determined by establish-
ing the amplitude of the ‘‘putative’’ rod response from a twin-flash
paradigm at 2.07 log cd.s.m2. By using a 500-ms interstimulus
interval, the long refractory period of the rod system means that only
cone responses are recorded in the second flash, which is then
subtracted from the mixed response to return the putative rod
response. Group data for rod amplitude (at 2.07 log cd.s.m2) was
compared with the amplitude of mixed responses for all other
luminous energies. Amplitudes for luminous energies greater than
0.82 log cd.s.m2 were found to be significantly larger than the
isolated rod PII amplitude (P < 0.05), indicating significant cone
contribution. Thus, Equation 2 was fit to luminous energies between
6.79 to 0.82 log cd.s.m2, as well as the isolated rod PII at 2.07 log
cd.s.m2 by minimizing the sum-of-squares merit function using the
Excel Solver module (Microsoft).
Scotopic Threshold Response. Amplitudes of the STR were
evaluated for luminous energies between 6.79 and 5.25 log
cd.s.m2 by taking the amplitude at a fixed time of 110 and 220 ms
to return positive (pSTR) and negative (nSTR) components, respec-
tively.
Susceptibility to IOP Elevation. The change in ERG or ocular
blood flow at each IOP level was expressed as a percentage relative to
responses collected at baseline IOP of 10 mm Hg (stress/baseline, %).
As previous,20 an inverse cumulative normal function (Equation 320)
was used to paramatize the relationship between relative (mean 6
SEM) ERG amplitudes as a function of IOP. This function was applied
assuming a maximum of 100%, to return best-fit parameters for the
mean (l) and 1/slope (r). The mean represents the IOP level at which
the response has been reduced to 50% (IOP50) and 1/slope represents
the steepness of the curve.
f ðxÞ ¼ 1 1ﬃﬃﬃﬃﬃﬃﬃﬃ
2pr
p e ðxlÞ
2
2r2
 
ð3Þ
TABLE 2. Oligonucleotide Primers for Nitric Oxide Synthase Isoenzymes (eNos, iNos, and nNos) and the Housekeeper Gene, HPRT
Gene
Accession No.
(PubMed.org) Primer Sequences Source Organism Amplicon Size, bp
eNos NM_021838.260 F: 50-TGGCAGCCCTAAGACCTATG-30 Rattus norvegicus (Norway rat) 243
R:50-AGTCCGAAAATGTCCTCGTG-30
iNos NM_012611.360 F: 50-CCTTGTTCAGCTACGCCTTC-30 Rattus norvegicus (Norway rat) 179
R:50-GGTATGCCCGAGTTCTTTCA-30
nNos NM_052799.161 F: 50-CCTTCCGAAGCTTCTGGCAACAGC-30 Rattus norvegicus (Norway rat) 474
R:50-TGGACTCAGATCTAAGGCGGTTGG-30
HPRT NM_000194.262 F: 50-GGAGGCCATCACATTGTAGC-30 Homo sapiens (Human) 229
R:50-CCACAATCAAGACATTCTTTC-30
F, forward; R, reverse.
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Statistics
To compare blood glucose, baseline IOP, SBP, and ERG, as well as
changes in Nos expression, the following statistics were employed. A
Kolmogorov-Smirnov normality test and Barlett’s test for equal variance
were performed before comparing treatments. Data showing normality
and equal variances were analyzed using parametric analysis, such as
unpaired or paired t-test, repeated measures ANOVA (RM-ANOVA), one-
way ANOVA, and two-way ANOVA. For one-way ANOVA analysis, a
Dunnett’s post hoc test was applied to determine significant
departures from baseline. For data failing criteria for parametric
statistics, two approaches were used. First, for comparisons involving
multiple factors (treatment and IOP), a more conservative a-value of
0.035 was used to protect against false positives. Second, for
comparison of a single factor between STZ-diabetic and citrate animals,
a nonparametric Mann-Whitney test was adopted.
As previous,20 to compare the susceptibility of citrate and STZ-
diabetic ERG and blood flow to IOP elevation, a bootstrap method was
used to generate estimates of the mean and 95% confidence limits (CLs)
for IOP50 (l) and 1/slope (r). This approach has the advantage that it
does not make any assumptions regarding the underlying distribution
of the data and provides a more robust estimate of parameter variability
in transition functions, such as in Equation 3.33,34 As previous,35 each
iterative bootstrap sample consisted of n random selections taken
(with replacement) from each group. The bootstrap sample was then
modeled as a function of IOP using Equation 3, to return IOP50 and 1/
slope for this particular sample. After 1000 iterations, the 25th and
97th percentiles were taken as the ‘‘bootstrap’’ bounds of the 95% CL.
This approach allows a robust comparison of the relative sensitivity of
various citrate and STZ-diabetic eyes to IOP elevation. When the best-fit
parameter of the STZ-diabetic group falls outside the 95% CL of the
respective parameter for the citrate group, then P is less than 0.05.
RESULTS
Table 1 shows that at 1 (P < 0.001) and 2 weeks following STZ
injection (P < 0.001), there was significant elevation of blood
glucose in STZ-treated animals compared with citrate controls.
It has been reported that systemic hyperglycemia can modify
IOP and blood pressure,36 which may modify ocular perfusion
pressure (OPP), an important determinant of ocular blood
flow. Noninvasive measurement of baseline IOP revealed no
significant difference between citrate and diabetic groups (P¼
0.932; Table 1). SBP was similar when measured noninvasively
at the beginning (citrate versus STZ, P¼ 0.991; BP 1) and end
of the IOP challenge protocol (P¼0.116; BP 2). Although there
was a small decrease in SBP from the beginning to the end of
the experimental protocol, this was not statistically significant
for citrate (P ¼ 0.073) and STZ-diabetic animals (P ¼ 0.325).
Baseline ERG: STR and b-Wave
Figure 1 shows retinal function across a range of luminous
energies recorded at baseline and 3 weeks following citrate
(thin traces) or STZ (thick traces) injection. Three weeks of
hyperglycemia had little obvious effect on the ERG in citrate
and STZ-diabetic animals.
Saturated phototransduction amplitude (RmPIII, Fig. 2A) and
sensitivity (S) (Fig. 2B) were not significantly different between
citrate and diabetic eyes (RmPIII: P ¼ 0.70, S: P ¼ 0.76). The
ERG PII (reflecting ON-bipolar cell function) was assessed by
fitting the luminous energy-response function for amplitudes
taken at a fixed time of 70 ms with a saturating hyperbolic
function (Equation 2). The saturated ON-bipolar cell amplitude
was not significantly different between STZ-diabetic and citrate
eyes (Vmax, P ¼ 0.657; Fig. 2C). However, there was a
significant reduction in the PII sensitivity in the STZ group
when compared with citrate controls (1/k: P¼ 0.006; Fig. 2D).
The retinal ganglion cell response as given by STR
amplitudes at a fixed time of 110 ms (Fig. 2E) was
significantly reduced in the diabetic group (P < 0.001). On
the other hand, the amplitude at 220 ms was larger in the STZ
group (P¼ 0.024; Fig. 2F). The STZ-treated group also showed
a delay in the pSTR (P ¼ 0.016; Fig. 2G); however, nSTR
implicit time (P¼ 0.847; Fig. 2H) was similar to citrate control
eyes.
Effect of Acute IOP on Retinal Function in STZ-
Induced Diabetes
Figure 3 shows that both the ERG b-wave (Fig. 3A) and STR
(Fig. 3B) responses in STZ-diabetic eyes are more sensitive to
IOP elevation than the citrate group. Quantification using an
inverse cumulative normal function confirmed that STR and b-
wave amplitudes in STZ-diabetic eyes were significantly more
susceptible (l, IOP at 50% response reduction, IOP50) to IOP
elevation, as summarized in Table 3. Specifically, the STZ-
diabetic b-wave IOP-response function was 4.8 mm Hg (7.7%)
more susceptible (IOP50: 60.3 mm Hg, confidence interval
[CI]2.5–97.5: 58.0–62.8 mm Hg; Fig. 4A) than the citrate group
(IOP50: 65.1 mm Hg CI2.5–97.5: 61.9–68.6 mm Hg). The STR in
FIGURE 1. Comparison of retinal function between normal and
diabetic groups at 3 weeks post STZ-induction. (A) Representative
dark-adapted ERG waveforms for normal (thin trace) and diabetic
(thick trace) groups elicited across a wide range of luminous energies
(4.44 to 2.07 log cd.s.m2). (B) Representative scotopic threshold
responses elicited at dim light levels (6.79 to 5.25 log cd.s.m2).
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STZ animals was 7.4 mm Hg (11.6%) more susceptible (IOP50:
60.1 mm Hg, CI2.5–97.5: 57.0–62.0 mm Hg) in STZ-diabetic
animals than the citrate group (IOP50: 67.5, CI2.5–97.5: 62.1–
72.4 mm Hg; Table 3). No difference was found between the
slope of the inverse cumulative normal function for the b-wave
or STR (Table 3).
Effect of Acute IOP Elevation on Ocular Blood Flow
in STZ-Diabetes
To consider whether the increased functional susceptibility
observed in STZ-diabetic eyes was mediated by an impaired
blood flow response to stress, ocular blood flow was measured
in response to the same IOP challenge.
Similar to retinal function, ocular blood flow (Fig. 4A) in
STZ-diabetic eyes was almost 10 mm Hg more susceptible to
acute IOP challenge than the citrate group (STZ, IOP50: 43.9,
CI2.5–97.5: 40.8–46.8 mm Hg, filled symbols versus citrate,
IOP50, 53.4, CI2.5–97.5: 50.7–56.1 mm Hg, unfilled symbols;
Table 3). Table 3 also shows that no change was found in the
spread of the function (or sensitivity) between the STZ-diabetic
(r, 24.0, CI2.5–97.5: 20.6–27.1) and the citrate group (r, 26.1,
CI2.5–97.5: 21.9–30.0).
Figure 4B examines the relationship between retinal
function and ocular blood flow by taking the difference
between the STR and blood flow. These data show that for
IOPs below 80 mm Hg, blood flow is more affected than the
STR amplitude. Comparison between diabetic and citrate
groups suggests that for IOPs between 55 and 100 mm Hg
(P < 0.001), the gap between the STR and blood flow was
smaller in STZ-diabetic eyes than citrate control eyes. This
finding suggests that the relationship between blood flow
FIGURE 2. Comparison of parameters reflecting retinal cell function for normal (n ¼ 14, unfilled bars/symbols) and diabetic eyes (n ¼ 20, filled
bars/symbols). Averaged (6SEM) phototransduction saturated amplitude (A) RmPIII (lV) and (B) sensitivity (S, m2.cd1.s3). These parameters are
derived from an ensemble fit of the ERG a-wave elicited at 1.95 and 2.07 log cd.s.m2 (Equation 1). ON-bipolar cell function parameters (C) maximal
amplitude, Vmax (lV) and (D) sensitivity, 1/k (cd1.s1.m2) returned from a hyperbolic function (Methods, Equation 2) fitted to the averaged ERG b-
wave amplitudes taken at a fixed time of 70 ms, across a range of luminous energies (6.79 to 2.07 log cd.s.m2), anchored to the ‘‘putative’’ rod
ON-bipolar cells response (2.07 log cd.s.m2). Averaged inner retinal function (lV, scotopic threshold response, STR) measured at fixed times of (E)
110 and (F) 220 ms. Implicit times of (G) peak (pSTR) and (H) trough (nSTR) amplitudes of STR (6.79 to5.25 log cd.s.m2). Asterisks denote
significance (*P < 0.05, ***P < 0.001).
TABLE 3. Inverse Cumulative Normal Function Parameters (Susceptibility, l, and Spread, r) for Citrate and STZ-Diabetic Eyes
Inverse Cumulative Normal Function
Susceptibility, Functional IOP50, l, mm Hg 1/Slope, r
Best Fit, IOP50, mm Hg Difference 95% CI, 2.5 to 97.5% Best Fit 95% CI, 2.5 to 97.5%
ERG
Citrate b-wave 65.1 61.9 to 68.6 11.8 8.1 to 14.1
STZ b-wave 60.3* 4.8 (7.7%) 58.0 to 62.8 10.4 7.4 to 12.5
Citrate STR 67.5 62.1 to 72.4 12.0 5.0 to 15.1
STZ STR 60.1† 7.4 (11.6%) 57.0 to 62.0 10.4 5.4 to 12.3
OBF
Citrate 53.4 50.7 to 56.1 26.1 21.9 to 30.0
STZ 43.9‡ 40.8 to 46.8 24.0 20.6 to 27.1
* P ¼ 0.0038 compared with the lower limit citrate controls.
† P ¼ 0.016 compared with the lower limit citrate controls.
‡ P < 0.001compared with the lower limit citrate control.
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and retinal function during stress is altered in STZ-diabetic
eyes.
Effect of STZ-Diabetes and Acute IOP on NOS
mRNA Expression
Abnormal levels of Nos isoenzymes (eNos, iNos, and nNos)
are thought to contribute to vascular, neuronal, and glial
dysfunction.37–40 Thus, we considered if the increased
vulnerability to IOP challenge observed in STZ-diabetic eyes
was associated with changes in nitric oxide synthase activity.
Combining both control and IOP eyes, the STZ-diabetic group
(Fig. 5A) for mRNA expressions for eNos (citrate: 17.4 6 4.8
versus STZ: 13.3 6 3.9; P ¼ 0.153), nNos (citrate: 7.2 6 2.2
versus STZ: 7.2 6 3.1 [3 103 copies]; P ¼ 0.463), and iNos
(citrate: 0.6 6 0.2 versus STZ: 1.2 6 0.7 [3 102 copies]; P ¼
0.640) was not significantly different between diabetic and
citrate eyes. Interestingly, IOP challenge on mRNA expression
(%, Fig. 5B) increased eNos mRNA expression by 49.7% in
citrate control retinas, an effect significantly greater than the
STZ-diabetic group (5.7%, P ¼ 0.034). However, no
significant difference was found for nNos (P ¼ 0.789) and
iNos (P¼ 0.859) expression between citrate and STZ-diabetic
groups. In addition, the IOP-induced change in eNos mRNA
expression was significantly correlated with the susceptibility
of ocular blood flow to IOP challenge (IOP50, y ¼ 0.131x þ
46.8, rs ¼ 0.649, Spearman correlation, rs ¼ 0.649, P < 0.05,
Fig. 5C).
DISCUSSION
The key finding of this study was that as early as 4 weeks
following the onset of chronic hyperglycemia, before changes
in the major components of the ERG,18,41–43 retinal function
(Fig. 3) shows greater susceptibility to acute IOP challenge.
Although this is consistent with the work of Kanamori et al.,17
it is inconsistent with the study of Casson and colleagues.26
These authors reported that 5 days or 6 weeks post-STZ
injection (60 kg/mg; blood glucose: approximately 25 6 3.2
mM), b-wave recovery at 3 to 7 days following IOP elevation
to ischemic level (110 mm Hg) was better in diabetic eyes. It
may be that hyperglycemia is protective against ischemic
levels of IOP elevation of 110 mm Hg (as long as 60 minutes).
Indeed, a ‘‘protective’’ effect of hyperglycemia may be
important for neuronal viability under acute anaerobic
stress.44 The IOP used in this study only reached 100 mm
Hg for 3 minutes.
The increase in ERG susceptibility to IOP elevation was
associated with an increase in susceptibility in ocular blood
flow (Figs. 3B, 4A). Indeed, ocular blood flow in diabetic eyes
was 10 mm Hg more sensitive to IOP elevation than in the
citrate group (Fig. 4), which is somewhat similar to the
FIGURE 3. Comparison of relative (A) b-wave (ON-bipolar cells) and
(B) STR (inner retina) averaged (6SEM) amplitudes as a function of IOP
in citrate (unfilled symbols) and diabetic groups (filled symbols). IOP-
response relationships were described with use of an inverse
cumulative normal function (equation 3; citrate, thin curve, versus
diabetic, thick curve) to quantify change in amplitude as a function of
IOP. This function returns a best-fit l and r, which represents
sensitivity and spread, respectively. CIs for these parameters were
derived from a nonparametric bootstrap method (Table 3). Dotted and
dashed lines denote 0% and 100% relative amplitude, respectively.
FIGURE 4. Effect of acute IOP challenge on ocular blood flow in
normal (n ¼ 8, unfilled symbols) and diabetic animals (n ¼ 10, filled
symbols). (A) Averaged ocular blood flow (6SEM) relative to each eye’s
own baseline (100%, dashed line) for normal and diabetic groups. Each
curve was modeled with an inverse cumulative normal function
(equation 3) to quantify the effect between treatment groups. CIs for
these parameters were derived from a nonparametric bootstrap
method (Table 3). Dotted and dashed lines denote 0% and 100%
relative amplitude, respectively. (B) Difference (%) between relative
inner retinal function and ocular blood flow responses across
increasing IOP. Asterisks denote significance (***P < 0.001).
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increase in STR susceptibility of 7.4 mm Hg. This outcome is
consistent with a previous study45 using the blue field entoptic
technique to show that macular blood flow was compromised
with smaller IOP elevation in patients with mild or moderate
retinopathy (increase of 11 and 8 mm Hg, respectively)
compared with healthy individuals (15 mm Hg). This study
suggested that the effective autoregulatory range is compro-
mised with increasing severity of diabetic retinopathy. It is
worth noting that the LDF measure of blood flow receives
contributions from both retinal and choroidal circulations, thus
care must be taken when attributing the observed changes to
retinal autoregulation.
Impaired autoregulation, as evidenced by diminished retinal
vessel reactivity in the eye in response to perturbations, such
as oxygen breathing11 and flickering light,9,12,13,46 have been
reported in patients with diabetes. Impaired autoregulation
may be associated with vascular changes, such as loss of
pericytes and endothelial cells (as reviewed by Fletcher et al.47
and Hammes48),49 which are important in structural support
and autoregulation, respectively. Endothelial cells are an
important source of both endothelin and nitric oxide; thus,
their absence will impair autoregulation.
Several studies suggest that the bioavailability of nitric
oxide is altered by hyperglycemia. This change in nitric
oxide production has been attributed to disruption of eNOS
and nNOS activity.50 In this study, acute IOP challenge
produced a substantial increase in eNos mRNA expression in
citrate control animals but not STZ-rats (5.7%). It appears
that an IOP-induced increase in eNos is associated with
better blood flow resistance to acute IOP challenge (Fig.
5C). Previous studies have reported that well before the
onset of endothelial cell loss, and as early as 1 and 2 weeks
after treatment, there is detectable elevation of retinal eNos
and nNos levels in STZ-treated rat eyes compared with
healthy controls.51,52 Although the data were not significant,
there was a trend for increased eNos expression in STZ-
diabetic eyes (Fig. 5A). It has been suggested that
hyperglycemia-induced elevation of protein kinase C activity
could lead to the overproduction of nitric oxide,53 possibly
via upregulation of eNos. It has also been demonstrated that
in diabetic mice lacking iNos there was a significant
reduction in the number of acellular capillaries and pericyte
ghosts.49 Thus, iNOS54 is also likely to play an important
role in the increased sensitivity to IOP challenge observed in
our study.
Although our data argue that the functional susceptibility
arises from a vascular impairment, we cannot rule out the
possibility that in the STZ-diabetic eyes there is (1) reduced
neuronal redundancy due to cell loss or (2) hyperglycemia-
induced inherent neuronal susceptibility to IOP-related stress.
Although retinal cell loss has been described in laboratory and
clinical studies,55–57 such changes are usually noted 6 weeks
after STZ-injection.17,56 Kanamori et al.17 reported an 8- to 9-
fold increase in apoptotic cell death after 1 month of STZ-
diabetes in rats, of which the majority of these TUNEL
(terminal transferase dUTP nick end labeling)-positive cells
localized to the inner retinal layers. Thus, reduced neuronal
redundancy could contribute to our observations. Consistent
with this possibility, the pSTR was reduced at baseline in our
STZ-diabetic rats, as has been reported elsewhere.41,43
Moreover, as IOP increased above 55 mm Hg, the buffer
between the STR amplitude and blood flow was reduced in
STZ-diabetic eyes compared with citrate controls (Fig. 4B).
This might suggest an additional neuronal susceptibility above
the observed impairment in blood flow autoregulation. An
inherent neuronal susceptibility might arise from increased
oxidative stress as evidenced by the reversal of axonal
transport and ion regulation abnormalities in mice overex-
pressing superoxide dismutase-258 and superoxide dismutase-
1,59 respectively.
CONCLUSIONS
Our study shows that retinal function in STZ-diabetic eyes is
more vulnerable to acute IOP challenge. This increased
susceptibility occurs very early in the course of STZ-induced
FIGURE 5. Effect of STZ-diabetes and acute IOP challenge on eNOS,
nNOS, and iNOS mRNA levels for citrate (unfilled bars) and STZ-
diabetic eyes (filled bars). (A) Diabetes effect on absolute copy number
relative to HPRT (averaged 6 SEM), showing combined control and
IOP-treated eyes. (B) Difference in effect of IOP treatment on mRNA
expression expressed relative to control eyes (%, treated-control/
control) for both conditions. Dashed line denotes 0%. Asterisk denotes
significance (*P < 0.05). (C) Relationship between susceptibility of
ocular blood flow to IOP elevation (IOP50) and IOP-induced changes in
eNos mRNA expression (%). A Deming linear regression, which takes
into account variability in both y- and x-axes and is thus more robust
for false positives and Spearman correlations (coefficient, rs) were
employed to describe the relationship (black line) between parame-
ters.
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diabetes, prior to severe retinal dysfunction. This was
associated with increased vulnerability of ocular blood flow
to IOP elevation, as well as a reduced capacity for diabetic eyes
to upregulate eNos in response to IOP stress.
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